Jae Yong Ryu

Prof. Dr. Jae Yong Ryu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2019 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
WJWoo Dae Jang
Woo Dae Jang
TKTae Yong Kim
Tae Yong Kim
Hyun Uk KimHyun Uk Kim
Hyun Uk Kim
WSWoo Yong Shim
Woo Yong Shim
JRJae Yong Ryu
Jae Yong Ryu
SLSang Yup Lee
Sang Yup Lee

13 September 2021 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
JRJae Yong Ryu
Jae Yong Ryu
JLJeong Hyun Lee
Jeong Hyun Lee
BLByung Ho Lee
Byung Ho Lee
JSJin Sook Song
Jin Sook Song
SASunjoo Ahn
Sunjoo Ahn
KOKwang-Seok Oh
Kwang-Seok Oh
Poor metabolic stability leads to drug development failure. Therefore, it is essential to evaluate the metabolic stability of small compounds for successful drug discovery and development. However, evaluating metabolic stability in vitro and in vivo is expensive, time-consuming and laborious. In addition, only a few free software programs are available for metabolic stability data and prediction. Therefore, in this study, we aimed to develop a prediction model that predicts the metabolic stability of small compounds. We developed a computational model, PredMS, which predicts the metabolic stability of small compounds as stable or unstable in human liver microsomes. PredMS is based on a random forest model using an in-house database of metabolic stability data of 1917 compounds. To validate the prediction performance of PredMS, we generated external test data of 61 compounds. PredMS achieved an accuracy of 0.74, Matthew’s correlation coefficient of 0.48, sensitivity of 0.70, specificity of 0.86, positive predictive value of 0.94 and negative predictive value of 0.46 on the external test dataset. PredMS will be a useful tool to predict the metabolic stability of small compounds in the early stages of drug discovery and development. The source code for PredMS is available at https://bitbucket.org/krictai/predms, and the PredMS web server is available at https://predms.netlify.app. Supplementary data are available at Bioinformatics online.

24 February 2023 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
JRJae Yong Ryu
Jae Yong Ryu
WJWoo Dae Jang
Woo Dae Jang
JJJidon Jang
Jidon Jang
KOKwang-Seok Oh
Kwang-Seok Oh
Background: Acute oral toxicity of drug candidates can lead to drug development failure; thus, predicting the acute oral toxicity of small compounds is important for successful drug development. However, evaluation of the acute oral toxicity of small compounds considered in the early stages of drug discovery is limited because of cost and time. Here, we developed a computational framework, PredAOT, that predicts the acute oral toxicity of small compounds in mice and rats. Methods: PredAOT is based on multiple random forest models for the accurate prediction of acute oral toxicity. A total of 6226 and 6238 compounds evaluated in mice and rats, respectively, were used to train the models. Results: PredAOT has the advantage of predicting acute oral toxicity in mice and rats simultaneously, and its prediction performance is similar to or better than that of existing tools. Conclusion: PredAOT will be a useful tool for the quick and accurate prediction of the acute oral toxicity of small compounds in mice and rats during drug development.

2 January 2021 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
YKYeji Kim
Yeji Kim
JRJae Yong Ryu
Jae Yong Ryu
Hyun Uk KimHyun Uk Kim
Hyun Uk Kim
WJWoo Dae Jang
Woo Dae Jang
SLSang Yup Lee
Sang Yup Lee

15 February 2024 in Hepatology
Verified
Journal Article
Closed access
JPJong Geun Park
Jong Geun Park
PRPu Reun Roh
Pu Reun Roh
MKMin Woo Kang
Min Woo Kang
SCSung Woo Cho
Sung Woo Cho
SHSuhyun Hwangbo
Suhyun Hwangbo
PSPil Soo Sung
Pil Soo Sung
Background and Aims: Cancer-associated fibroblasts (CAFs) play key roles in the tumor microenvironment. IgA contributes to inflammation and dismantling antitumor immunity in the human liver. In this study, we aimed to elucidate the effects of the IgA complex on CAFs in Pil Soo Sung the tumor microenvironment of HCC. Approach and Results: CAF dynamics in HCC tumor microenvironment were analyzed through single-cell RNA sequencing of HCC samples. CAFs isolated from 50 HCC samples were treated with mock or serum-derived IgA dimers in vitro. Progression-free survival of patients with advanced HCC treated with atezolizumab and bevacizumab was significantly longer in those with low serum IgA levels (p<0.05). Single-cell analysis showed that subcluster proportions in the CAF-fibroblast activation protein-α matrix were significantly increased in patients with high serum IgA levels. Flow cytometry revealed a significant increase in the mean fluorescence intensity of fibroblast activation protein in the CD68+ cells from patients with high serum IgA levels (p<0.001). We confirmed CD71 (IgA receptor) expression in CAFs, and IgA-treated CAFs exhibited higher programmed death-ligand 1 expression levels than those in mock-treated CAFs (p<0.05). Coculture with CAFs attenuated the cytotoxic function of activated CD8+ T cells. Interestingly, activated CD8+ T cells cocultured with IgA-treated CAFs exhibited increased programmed death-1 expression levels than those cocultured with mock-treated CAFs (p<0.05). Conclusions: Intrahepatic IgA induced polarization of HCC-CAFs into more malignant matrix phenotypes and attenuates cytotoxic T-cell function. Our study highlighted their potential roles in tumor progression and immune suppression.

24 August 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GLGyutae Lim
Gyutae Lim
CLChae Jo Lim
Chae Jo Lim
JLJeong Hyun Lee
Jeong Hyun Lee
BLByung Ho Lee
Byung Ho Lee
JRJae Yong Ryu
Jae Yong Ryu
KOKwang-Seok Oh
Kwang-Seok Oh
Drug repositioning research using transcriptome data has recently attracted attention. In this study, we attempted to identify new target proteins of the urotensin-II receptor antagonist, KR-37524 (4-(3-bromo-4-(piperidin-4-yloxy)benzyl)-N-(3-(dimethylamino)phenyl)piperazine-1-carboxamide dihydrochloride), using a transcriptome-based drug repositioning approach. To do this, we obtained KR-37524-induced gene expression profile changes in four cell lines (A375, A549, MCF7, and PC3), and compared them with the approved drug-induced gene expression profile changes available in the LINCS L1000 database to identify approved drugs with similar gene expression profile changes. Here, the similarity between the two gene expression profile changes was calculated using the connectivity score. We then selected proteins that are known targets of the top three approved drugs with the highest connectivity score in each cell line (12 drugs in total) as potential targets of KR-37524. Seven potential target proteins were experimentally confirmed using an in vitro binding assay. Through this analysis, we identified that neurologically regulated serotonin transporter proteins are new target proteins of KR-37524. These results indicate that the transcriptome-based drug repositioning approach can be used to identify new target proteins of a given compound, and we provide a standalone software developed in this study that will serve as a useful tool for drug repositioning.